Literature DB >> 12203768

In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging.

Bashar Issa1.   

Abstract

PURPOSE: To measure for the first time the apparent diffusion coefficient (ADC) values in anatomical regions of the prostate for normal and patient groups, and to investigate its use as a differentiating parameter between healthy and malignant tissue within the patient group.
MATERIALS AND METHODS: Single-shot diffusion-weighted echo-planar imaging (DW-EPI) was used to measure the ADC in the prostate in normal (N = 7) and patient (N = 19) groups. The spin-echo images comprised 96 x 96 pixels (field of view of 16 cm, TR/TE = 4000/120 msec) with six b-factor values ranging from 64 to 786 seconds/mm(2).
RESULTS: The ADC values averaged over all patients in non-cancerous and malignant peripheral zone (PZ) tissues were 1.82 +/- 0.53 x 10(-3) (mean +/- SD) and 1.38 +/- 0.52 x 10(-3) mm(2)/second, respectively (P = 0.00045, N = 17, paired t-test). The ADC values were found to be higher in the non-cancerous PZ (1.88 +/- 0.48 x 10(-3)) than in healthy or benign prostatic hyperplasia central gland (BPH-CG) region (1.62 +/- 0.41 x 10(-3)). For the normal group, the mean values were 1.91 +/- 0.46 x 10(-3) and 1.63 +/- 0.30 x 10(-3) mm(2)/second for the PZ and CG, respectively (P = 0.011, N = 7). Significant overlap exists between individual values among all tissue types. Furthermore, ADC values for the same tissue type showed no statistically significant difference between the two subject groups.
CONCLUSION: ADC is quantified in the prostate using DW-EPI. Values are lower in cancerous than in healthy PZ in patients, and in BPH-CG than PZ in volunteers. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12203768     DOI: 10.1002/jmri.10139

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  59 in total

1.  Role of diffusion-weighted magnetic resonance imaging in the diagnosis of extrahepatic cholangiocarcinoma.

Authors:  Xing-Yu Cui; Hong-Wei Chen
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

Review 2.  Diffusion weighted imaging in prostate cancer.

Authors:  Cher Heng Tan; Jihong Wang; Vikas Kundra
Journal:  Eur Radiol       Date:  2010-10-09       Impact factor: 5.315

3.  In vivo 3T and ex vivo 7T diffusion tensor imaging of prostate cancer: Correlation with histology.

Authors:  Carlos F Uribe; Edward C Jones; Silvia D Chang; S Larry Goldenberg; Stefan A Reinsberg; Piotr Kozlowski
Journal:  Magn Reson Imaging       Date:  2015-02-24       Impact factor: 2.546

Review 4.  Extracranial applications of diffusion-weighted magnetic resonance imaging.

Authors:  Harriet C Thoeny; Frederik De Keyzer
Journal:  Eur Radiol       Date:  2007-01-06       Impact factor: 5.315

5.  Diffusion tensor imaging of the normal prostate at 3 Tesla.

Authors:  Bengi Gürses; Neslihan Kabakci; Arzu Kovanlikaya; Zeynep Firat; Ali Bayram; Aziz Müfit Uluğ; Aziz Müfit Uluo; Ilhami Kovanlikaya
Journal:  Eur Radiol       Date:  2007-10-25       Impact factor: 5.315

6.  Utility of ADC measurement on diffusion-weighted MRI in differentiation of prostate cancer, normal prostate and prostatitis.

Authors:  Meltem Esen; Mehmet Ruhi Onur; Nusret Akpolat; Irfan Orhan; Ercan Kocakoc
Journal:  Quant Imaging Med Surg       Date:  2013-08

Review 7.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

8.  The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach.

Authors:  B Nicolas Bloch; Robert E Lenkinski; Neil M Rofsky
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

Review 9.  Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer.

Authors:  Michael A Jacobs; Ronald Ouwerkerk; Kyle Petrowski; Katarzyna J Macura
Journal:  Top Magn Reson Imaging       Date:  2008-12

10.  Carr-Purcell-Meiboom-Gill imaging of prostate cancer: quantitative T2 values for cancer discrimination.

Authors:  Joseph R Roebuck; Steven J Haker; Dimitris Mitsouras; Frank J Rybicki; Clare M Tempany; Robert V Mulkern
Journal:  Magn Reson Imaging       Date:  2008-09-26       Impact factor: 2.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.